Hanmi Science. has developed a novel anti-PD-L1/anti-4-1BB bispecific antibody with natural IgG features, offering enhanced stability and efficacy in treating complex diseases with fewer side effects. The antibody simultaneously binds two target molecules, providing a promising therapeutic option. GlobalData’s report on Hanmi Science gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Hanmi Science Co Ltd - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Hanmi Science, Hormone-based therapies for metabolic disorders was a key innovation area identified from patents. Hanmi Science's grant share as of January 2024 was 36%. Grant share is based on the ratio of number of grants to total number of patents.

Bispecific antibody for pd-l1 and 4-1bb targeting

Source: United States Patent and Trademark Office (USPTO). Credit: Hanmi Science Co Ltd

A recently filed patent (Publication Number: US20240034801A1) describes a bispecific antibody designed to target two specific proteins, PD-L1 and 4-1BB. The antibody consists of two antigen-binding functional regions, one that binds to PD-L1 and the other to 4-1BB. The sequences of the heavy and light chain variable regions for each antigen-binding region are specified in the patent claims, providing detailed information on the composition of the bispecific antibody.

Moreover, the patent claims cover various aspects of the bispecific antibody, including the use of Fab fragments, scFv fragments, and Fv variable domain fragments, as well as the incorporation of Fc chains with specific amino acid substitutions. The patent also includes details on the weight ratios of the polypeptide chains in the antibody and the specific sequences of the heavy and light chain pairs that bind to PD-L1 and 4-1BB. Additionally, the patent extends to an isolated polynucleotide encoding the bispecific antibody and a composition comprising the antibody and a pharmaceutically acceptable carrier, potentially for use in preventing and treating diseases such as leukemia, lymphoma, and various types of cancer in mammals, including humans.

To know more about GlobalData’s detailed insights on Hanmi Science, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies